

Benjamin J Solomon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8645620/benjamin-j-solomon-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194 papers	28,029 citations	59 h-index	167 g-index
217 ext. papers	34,099 ext. citations	9.6 avg, IF	6.6 L-index

#	Paper	IF	Citations
194	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.. <i>The Cochrane Library</i> , 2022 , 1, CD013453	5.2	0
193	Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	2
192	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
191	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) 2021 , 9,		5
190	Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2446-2456	6.1	3
189	Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease.. <i>JCO Precision Oncology</i> , 2021 , 5, 561-568	3.6	0
188	Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. <i>Journal of Cancer Survivorship</i> , 2021 , 15, 392-397	5.1	5
187	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 313-319	19.4	59
186	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021 , 5, 33	9.8	2
185	Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9065-9065	2.2	2
184	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. <i>Nature Communications</i> , 2021 , 12, 3236	17.4	22
183	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. <i>Annals of Oncology</i> , 2021 , 32, 620-630	10.3	14
182	Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 109-109	2.2	1
181	Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9032-9032	2.2	0
180	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e859-e869	4.9	6
179	Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2736-2751	4.4	2
178	Nuclear protein in testis carcinoma: a diagnostic and therapeutic challenge. <i>Internal Medicine Journal</i> , 2021 , 51, 1191-1192	1.6	

177	Functional and patient-reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limited-stage small-cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021 , 65, 786-795	1.7	
176	Phase III study of selpercatinib versus chemotherapy + pembrolizumab in untreated positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021 , 17, 763-773	3.6	13
175	A Phase 1 and Biodistribution Study of ABT-806i, an In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 787-794	8.9	1
174	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 359-367	1.9	27
173	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. <i>JCO Precision Oncology</i> , 2021 , 5, 1160-1165	3.6	1
172	Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3446-3456	4.4	1
171	Lung cancer. <i>Lancet, The</i> , 2021 , 398, 535-554	4.0	115
170	Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results. <i>Internal Medicine Journal</i> , 2021 , 51, 1355-1356	1.6	
169	Alectinib induces marked red cell spherocanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding. <i>Pathology</i> , 2021 , 53, 608-612	1.6	4
168	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. <i>Future Oncology</i> , 2021 , 17, 4649-4656	3.6	
167	Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. <i>ESMO Open</i> , 2021 , 6, 100224	6	2
166	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. <i>Nature Immunology</i> , 2020 , 21, 914-926	19.1	53
165	Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 145, 167-172	5.9	1
164	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020 , 212, 481-489	4	66
163	Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-6	7.1	5
162	Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma. <i>Oncogene</i> , 2020 , 39, 5177-5186	9.2	2
161	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. <i>Cancers</i> , 2020 , 12,	6.6	12
160	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2140-2150	2.2	28

159	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 144, 10-19	5.9	8
158	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 146, 310-317	5.9	11
157	Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC". <i>Journal of Thoracic Oncology</i> , 2020 , 15, e127-e128	8.9	1
156	Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 21, 85-90	4.6	4
155	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020 , 26, 47-51	50.5	134
154	RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 541-549	8.9	83
153	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 142, 34-40	5.9	16
152	Validation and characterisation of prognostically significant PD-L1 immune cells in HPV+ oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020 , 101, 104516	4.4	9
151	Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study. <i>Oral Oncology</i> , 2020 , 110, 104988	4.4	2
150	First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2018-2029	59.2	196
149	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020 , 5, e001090	6	9
148	Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients. <i>JAMIA Open</i> , 2020 , 3, 209-215	2.9	4
147	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020 , 28, 2379-2393	11.7	19
146	Efficacy of Selpercatinib in -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020 , 383, 825-835	59.2	166
145	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 813-824	59.2	194
144	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019 , 36, 385-401.e8	24.3	169
143	Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1134-1155	8.9	47
142	Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	65

141	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019 , 24, 1103-1110	5.7	44
140	Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1370-1379	2.2	154
139	Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 494-503	21.7	206
138	Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. <i>Drugs</i> , 2019 , 79, 1277-1286	12.1	20
137	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , 2019 , 29, 1634-1645	6.2	25
136	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1691-1701	21.7	136
135	Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. <i>Translational Lung Cancer Research</i> , 2019 , 8, 167-175	4.4	4
134	Radiotherapy and immunotherapy: a synergistic effect in cancer care. <i>Medical Journal of Australia</i> , 2019 , 210, 47-53	4	25
133	Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	18
132	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 323-358	8.9	241
131	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018 , 52, 228-240	12.7	162
130	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 221-246	5	371
129	Prognostic Significance of PD-L1 and CD8 Immune Cells in HPV Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 295-304	12.5	65
128	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 129-159	5.1	165
127	Treatment of ALK-positive nonsmall cell lung cancer: recent advances. <i>Current Opinion in Oncology</i> , 2018 , 30, 84-91	4.2	23
126	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018 , 9, 1048	17.4	152
125	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. <i>Internal Medicine Journal</i> , 2018 , 48, 37-44	1.6	8
124	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. <i>PET Clinics</i> , 2018 , 13, 33-42	2.2	2

123	Avelumab (antiPD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9008-9008	2.2	32
122	Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018 , 50, 691-700	5.2	30
121	Thromboembolism in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, e71-e72	4.9	11
120	Navigating Through New, First-Line Treatment Options for Lung Cancer. <i>Journal of Oncology Practice</i> , 2018 , 14, 539-540	3.1	
119	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2251-2258	2.2	197
118	Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an Tyrosine Kinase Inhibitor.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-13	3.6	2
117	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018 , 105, 88-102	7.5	37
116	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 1654-1667	21.7	361
115	Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System. <i>Clinical Lung Cancer</i> , 2018 , 19, e933-e944	4.9	15
114	First-line treatment options for ALK-rearranged lung cancer. <i>Lancet, The</i> , 2017 , 389, 884-886	4.0	6
113	Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. <i>Cancer Imaging</i> , 2017 , 17, 7	5.6	15
112	Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 948-954	4	3
111	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29
110	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1610-1622	6.1	16
109	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1590-1599	21.7	367
108	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. <i>Medical Oncology</i> , 2017 , 34, 175	3.7	4
107	Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2017 , 117, 744-751	8.7	41
106	Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. <i>Pathology</i> , 2017 , 49, 604-610	1.6	9

105	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Esophageal, Gastric, Pancreatic and Primary Biliary Tumors. <i>Advances in Immunology</i> , 2017 , 161, 1-25	5.1	299
104	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Immunology</i> , 2017 , 161, 26-55	5.1	293
103	Impact of sex on prognostic host factors in surgical patients with lung cancer. <i>ANZ Journal of Surgery</i> , 2017 , 87, 1015-1020	1	8
102	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017 , 2, e000219	6	62
101	Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9006-9006	2.2	15
100	Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1522-8	8.9	10
99	A New Theranostic Paradigm for Advanced Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1493-1494	14.94	8
98	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 452-463	21.7	318
97	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 737-747	8.9	42
96	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016 , 22, 2386-95	12.9	138
95	Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9009-9009	2.2	44
94	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016 , 7, 621	8.4	90
93	p16-positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high-risk human papillomavirus or prognosis and implications for the workup of the unknown primary. <i>Cancer</i> , 2016 , 122, 1201-8	6.4	34
92	BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 249-54	7.3	35
91	Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. <i>Clinical Epigenetics</i> , 2016 , 8, 74	7.7	3
90	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2858-65	2.2	171
89	The Influence of Comorbidity and the Simplified Comorbidity Score on Overall Survival in Non-Small Cell Lung Cancer-A Prospective Cohort Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 748-757	8.9	17
88	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016 , 34, 1010-1014	44.5	46

87	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. <i>Clinical Cancer Research</i> , 2015 , 21, 2745-52	12.9	133
86	Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 683-4	59.2	79
85	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015 , 524, 47-53	50.4	1061
84	Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. <i>Drugs</i> , 2015 , 75, 1059-70	12.1	15
83	Rociletinib in EGFR-mutated non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1700-9	59.2	524
82	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. <i>Genome Biology</i> , 2015 , 16, 7	18.3	39
81	Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 611-8	8.9	55
80	First-line crizotinib in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 782	59.2	18
79	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. <i>Cancer Research</i> , 2015 , 75, 4211-23	10.1	56
78	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2015 , 22, 1889-94	2.2	62
77	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 49	5.4	25
76	Complex renal cysts associated with crizotinib treatment. <i>Cancer Medicine</i> , 2015 , 4, 887-96	4.8	34
75	Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. <i>Blood</i> , 2015 , 126, 1257-8	2.2	31
74	Abiraterone in metastatic salivary duct carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 288-90	7.3	15
73	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. <i>PLoS ONE</i> , 2015 , 10, e0144559	3.7	38
72	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1881-8	2.2	454
71	Editor in Chief: Response to Eyre et al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease". <i>European Journal of Haematology</i> , 2015 , 94, 86-7	3.8	3
70	Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. <i>PLoS ONE</i> , 2015 , 10, e0142608	3.7	15

69	A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. <i>Scientific Reports</i> , 2014 , 4, 4186	4.9	27
68	Ceritinib in ALK-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 370, 1189-92	59.2	1119
67	Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1963-71	59.2	1267
66	Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. <i>International Journal of Cancer</i> , 2014 , 135, 887-95	7.5	42
65	Preoperative chemotherapy for non-small-cell lung cancer. <i>Lancet, The</i> , 2014 , 384, 232-3	40	4
64	DNA repair pathways and their therapeutic potential in lung cancer. <i>Lung Cancer Management</i> , 2014 , 3, 159-173	2.6	7
63	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014 , 5, 3518	17.4	173
62	CD74-NRG1 fusions in lung adenocarcinoma. <i>Cancer Discovery</i> , 2014 , 4, 415-22	24.4	173
61	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014 , 20, 1027-34	50.5	191
60	Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 385-94	4	15
59	Response. <i>Chest</i> , 2014 , 145, 666	5.3	
58	Response to Mahe. <i>Modern Pathology</i> , 2014 , 27, 1424-5	9.8	1
57	Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH. <i>Modern Pathology</i> , 2014 , 27, 1621-31	9.8	13
56	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 2167-77	59.2	2116
55	Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. <i>Clinical Epigenetics</i> , 2014 , 6, 22	7.7	17
54	Absence of a relationship between tumor 18 F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 377-82	8.9	15
53	. <i>Clinical and Translational Imaging</i> , 2014 , 2, 5-12	2	1
52	Phase Ib/II study of the PI3K β inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6044-6044	2.2	13

51	First-line crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014 , 32, 8002-8002	2.2	30
50	Weekly cisplatin and radiotherapy for low-risk human papillomavirus positive oropharyngeal squamous cell carcinoma (HPVOPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17017-e17017	2.2	
49	Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. <i>Oral Oncology</i> , 2013 , 49, 576-81	4.4	28
48	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. <i>Modern Pathology</i> , 2013 , 26, 1545-53	9.8	119
47	Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation. <i>Clinical Lung Cancer</i> , 2013 , 14, 508-12	4.9	11
46	Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 636-43	4.9	22
45	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 2385-94	59.2	2594
44	Suicide in lung cancer: who is at risk?. <i>Chest</i> , 2013 , 144, 1245-1252	5.3	38
43	Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 940-6	8.9	49
42	A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2520-2520	2.2	15
41	Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8032-8032	2.2	26
40	Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8105-8105	2.2	1
39	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. <i>Journal of Thoracic Disease</i> , 2013 , 5 Suppl 5, S579-92	2.6	29
38	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology, The</i> , 2012 , 13, 1011-9	21.7	983
37	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1104-10	36.3	919
36	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2012 , 48, 698-702	4.4	8
35	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. <i>Journal of Personalized Medicine</i> , 2012 , 2, 35-49	3.6	6
34	Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1676-85	8.9	7

33	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. <i>Science Translational Medicine</i> , 2012 , 4, 120ra17	17.5	948
32	Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements. <i>Clinical Investigation</i> , 2012 , 2, 895-907		1
31	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7508-7508	2.2	46
30	A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7511-7511	2.2	5
29	Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7596-7596	2.2	6
28	Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7600-7600	2.2	14
27	Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK+ NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7601-7601	2.2	1
26	Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. <i>Molecular Cancer Research</i> , 2011 , 9, 1696-707	6.6	49
25	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology</i> , 2011 , 12, 1004-12	21.7	732
24	Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 2120-9	8.9	28
23	Crizotinib and testing for ALK. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1335-41	7.3	92
22	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 236-51	1.9	15
21	Targeting anaplastic lymphoma kinase in lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2081-6	12.9	230
20	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 942-6	8.9	354
19	Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1230-7	4	72
18	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4803-10	2.2	364
17	Differential (18)F-FDG and 3Pdeoxy-3P(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1261-7	8.9	28
16	Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. <i>Clinical Cancer Research</i> , 2011 , 17, 3304-15	12.9	111

15	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
14	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 2044-6	8.9	69
13	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1450-4	8.9	244
12	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4247-53	2.2	1462
11	An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 338-41	2.7	39
10	Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 787-91	8.9	25
9	Assessment of post-mortem-induced changes to the mouse brain proteome. <i>Journal of Neurochemistry</i> , 2008 , 105, 725-37	6	27
8	Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. <i>BMC Research Notes</i> , 2008 , 1, 14	2.3	35
7	M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S167-S168	8.9	
6	Adjuvant chemotherapy for non-small cell lung cancer. <i>Cancer Investigation</i> , 2007 , 25, 217-25	2.1	18
5	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 838-46	9.7	258
4	Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity. <i>Cancer Treatment Reviews</i> , 2005 , 31, 571-6	14.4	4
3	Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1417-22	6.1	46
2	EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 713-23	4	91
1	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic		4